GHRP-6
Growth Hormone-Releasing Peptide 6, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2
The Ground Truth Score
four plain questions, never one numberGHRP-6 does reliably spike GH in humans. The catch is intense hunger and cortisol/prolactin bleed at higher doses. No one has run the kind of trials that would tell you if any of that translates to outcomes that matter.
Bottom line
GHRP-6 is a synthetic hexapeptide that stimulates GH release by activating the ghrelin receptor (GHS-R1a), confirmed in human pharmacology studies since 1990, but it has never completed Phase III trials for any indication and all tissue-specific benefits (wound healing, cardioprotection) remain animal data only.
Does the science back it?
Do real people feel it?
Is it safe?
Could it be placebo?
"Do real people feel it?" is anecdote, not proof, weighted up because the science is thin, never because it beats a trial. And "could it be placebo?" is not an insult: if you feel better, that's real to you. The point is only to know whether you're paying peptide prices for an expectation.
Why is the evidence this thin? It's mostly economics →
Dose at a glance
full dosing ↓100-300 mcg SubQ 2-3x daily, fasted; no approved human protocol
Reported, not prescribed. Verify your vial and your math.
The gist
- The GH pulse is real and confirmed in humans since 1990, making GHRP-6 one of the better-evidenced gray-market peptides. The hunger that comes with it is not a side effect you can ignore.
- Beyond GH secretion, the claimed benefits like wound healing and cardioprotection are animal data only. No human outcome trial for body composition, recovery, or tissue repair has been completed.
- Going above roughly 300 mcg per injection does not buy more GH. It does buy more cortisol and prolactin, which is the opposite of what most people running this are after.
First documented human use
1990. Bowers CY et al. demonstrated GH-releasing potency and GHRH synergy in healthy male volunteers (J Clin Endocrinol Metab 1990;70(4):975-982, PMID 2108187).
The pitch
What people claim it does
Stated plainly and neutrally, exactly as you'll hear it. I grade each one below.
- Stimulates pulsatile GH release that mimics natural physiology
- Synergizes with GHRH analogs like CJC-1295 for stronger GH output
- May accelerate wound healing and tissue repair (animal data only; no replicated human trial exists)
- Cardioprotective effects suggested by animal studies only
- Useful for bulking due to strong appetite stimulation
The data behind each bullet
What actually backs it
GHRP-6 reliably increases GH secretion in humans
Multiple small human studies confirm acute GH pulse after IV and subcutaneous administration. Effects are dose-dependent. No long-duration RCTs on outcomes like body composition or recovery.
Bowers et al. 1990, J Clin Endocrinol Metab (PMID 2108187) ↗Combining GHRP-6 with GHRH produces synergistic GH release greater than either alone
Well-replicated in human studies. Complementary signaling pathways (PLC/calcium vs cAMP/PKA) explain the synergy mechanistically. Note: PMID 7617137 (Frieboes et al. 1995) is primarily a sleep-EEG and nocturnal secretion study that includes GHRP-6 data; it supports the GH and cortisol co-elevation finding but is not the canonical synergy demonstration paper. Synergy with GHRH was established in the Bowers 1990 and Popovic 1995 literature.
PMID 7617137, Neuroendocrinology 1995 (Frieboes et al.) ↗GHRP-6 improves wound healing
This grade reflects animal data only. PMID 27200188 (Mendoza Mari et al. 2016, Plastic Surgery International) is an animal study in Wistar rats and rabbit ear models, not a human trial. The claim previously described a 'small Cuban human trial (n=20)' but that characterization is incorrect: the published study contains no human subjects. No replicated human wound-healing trial for GHRP-6 exists in the indexed literature. Animal data shows improved granulation, angiogenesis, and anti-fibrotic effects.
PMID 27200188, Plastic Surgery International 2016 (Mendoza Mari et al.), animal study, rats and rabbits only ↗GHRP-6 protects the heart from cardiotoxic injury in animal models
Animal data only. The 2024 Frontiers in Pharmacology study demonstrated protection against doxorubicin-induced cardiotoxicity (not ischemia-reperfusion injury) in rats, via PI3K/Akt, Bcl-2 upregulation, and mitochondrial protection. The injury model is chemotherapy-induced cardiomyopathy, not ischemia-reperfusion. Zero controlled human cardiac trials exist.
Frontiers in Pharmacology 2024, DOI 10.3389/fphar.2024.1402138 (Berlanga-Acosta et al.), animal study, rats ↗GHRP-6 elevates cortisol and prolactin as a side effect
Confirmed in human pharmacology studies. At doses above approximately 1 mcg/kg, ACTH and cortisol are co-stimulated alongside GH. Prolactin also rises. Effect is dose-dependent.
PMID 10336729, J Neuroendocrinology 1999 (Frieboes et al.) ↗Mechanism
How it's assumed to work
Assumed · theoretical pathway
Assumed mechanism (confirmed in humans for GH release, but downstream effects are not proven in humans for most claimed benefits): GHRP-6 binds and activates GHS-R1a (the ghrelin receptor) in pituitary somatotrophs and hypothalamic neurons, triggering GH secretion via PLC/IP3/calcium signaling. This pathway is distinct from and synergistic with the GHRH/cAMP/PKA pathway. GHS-R1a activation also explains the strong orexigenic effect (hunger) and ACTH co-stimulation. Downstream benefits like tissue repair and cardioprotection are hypothesized to occur via GH and IGF-1 elevation plus direct GHS-R1a signaling in peripheral tissues, but this chain has not been demonstrated in human outcome trials.
Dosing & handling
What users and clinicians report
100 mcg subcutaneous injection, 1-3 times per day. Commonly injected fasted (pre-workout or before bed) to avoid blunting the GH pulse with carbohydrates. Some users go up to 300 mcg per injection. Often paired with a GHRH analog dosed simultaneously.
Reported doses are from bodybuilding community protocols, not from any approved prescribing information. GHRP-6 is not approved for human use anywhere. The biggest dosing risk is that doses above the saturation point (roughly 1 mcg/kg) meaningfully elevate cortisol and prolactin without producing proportionally more GH, creating a worse risk/benefit ratio at higher doses. Gray-market vial purity is unverified.
Timing & food
Fasted state strongly preferred. Food (especially carbohydrates) raises somatostatin and blunts the GH pulse. Common windows are pre-workout (fasted AM) and immediately before bed. Waiting at least 2 hours after a meal is the standard community guidance.
Half-life
Bi-exponential: distribution half-life approximately 7-8 minutes, elimination half-life approximately 2-2.5 hours after IV administration. Subcutaneous GH-stimulating effect peaks within 15-30 minutes and returns to baseline within 2-3 hours.
Reconstitution sensitivity
Moderate. Reconstitute with bacteriostatic water. Stable refrigerated for approximately 30 days post-reconstitution. Sensitive to heat and repeated freeze-thaw cycles. Avoid vigorous shaking.
Real-world signal
What people actually report
Anecdote, not proof, weighted because the science is thin. Here's the record, graded on volume, consistency, and how credible the sources are.
Volume
High community usage volume, particularly in bodybuilding and performance optimization forums. GHRP-6 has been in gray-market circulation for 20+ years and there are large bodies of anecdotal user logs.
Consistency
The hunger side effect is reported with near-universal consistency, which adds credibility since it is a pharmacologically expected consequence of GHS-R1a activation. GH pulse effects are directionally consistent with lab data. Body composition and recovery benefits are inconsistent across anecdotal reports.
Source credibility
Lower than volume would suggest. Most community logs do not control for concurrent TRT, other peptides, training changes, or caloric intake. The hunger effect is the only truly credible signal because it is objective, immediate, and pharmacologically explained.
- Anecdote: Intense hunger within 20-30 minutes of injection is the most consistently reported effect, described as distracting and sometimes difficult to manage on a caloric deficit.
- Anecdote: Users on GHRP-6 plus CJC-1295 stacks report improved sleep quality and more vivid dreams, which they attribute to augmented GH pulses during slow-wave sleep.
- Anecdote: Recovery between training sessions is commonly reported as faster, though nearly all reports involve multiple stacked compounds making attribution impossible.
- Anecdote: Water retention and a slightly puffy face are reported within the first 1-2 weeks and often resolve with continued use. Some users discontinue because of this.
Placebo risk, Moderate
The GH pulse itself is objective and measurable, and the hunger effect is a real pharmacological action. However, subjective benefits like improved recovery, better sleep, and muscle growth are easily confounded by expectation, training variables, and concurrent compounds. Most users cannot measure their own GH pulses, so the subjective experience is the primary feedback loop.
Risk panel
What could go wrong
Adverse events
Intense hunger within 15-30 minutes of injection is nearly universal and is the most commonly reported reason for discontinuation. Mild water retention, transient flushing, and tingling have been reported. Elevated cortisol (via ACTH co-stimulation) is dose-dependent and real. Elevated prolactin at higher doses. No serious adverse events attributed to GHRP-6 in published human studies, but sample sizes are small and follow-up duration is short.
Theoretical concerns
Chronic GH elevation may impair glucose metabolism and insulin sensitivity. Persistent cortisol elevation would be counterproductive for recovery and body composition. Unknown long-term effects on pituitary axis regulation. Theoretical tumor-promotion risk with elevated IGF-1 applies to all GH secretagogues.
Contraindications
Active cancer or history of hormone-sensitive malignancies. Insulin resistance or pre-diabetes (GH blunts insulin sensitivity). Pregnancy and breastfeeding (no safety data). Use with caution in anyone with elevated baseline cortisol.
Honest unknowns
No long-duration human trials. Purity and actual peptide content of gray-market research-chemical supply is unverified. Receptor desensitization kinetics over weeks-to-months of use are not well characterized in humans. Interaction with exogenous testosterone or GLP-1 agonists is unknown. No human wound-healing or cardiac outcome trials have been completed.
Confound watch
Almost universally stacked with CJC-1295 or modified GRF(1-29) in the wellness community, making it impossible to isolate GHRP-6 contribution from community reports. Many users are also on TRT, which independently improves body composition and recovery. GLP-1 agonists (semaglutide, tirzepatide) directly suppress appetite and could mask or counteract GHRP-6's orexigenic effect. Sleep quality improvements often attributed to GHRP-6 may reflect the natural GH pulse that accompanies deeper sleep rather than a drug effect.
History
Discovery → first use → status
- 1984Cyril Y. Bowers at Tulane University synthesizes GHRP-6, the first synthetic GH secretagogue, during enkephalin analog research. It becomes the founding compound of the entire GHRP family.
- 1990First published human data: Bowers et al. (PMID 2108187) confirm GHRP-6 stimulates GH release in 17 healthy men and acts synergistically with GHRH, establishing the basis for all subsequent clinical interest.
- 1996GHS-R1a receptor (the ghrelin receptor) is cloned, providing a molecular explanation for GHRP-6's mechanism. GHRP-6 research directly enabled Kojima et al.'s 1999 discovery of endogenous ghrelin.
- 2016Cuban research group publishes animal wound-healing study (PMID 27200188, Plastic Surgery International) showing GHRP-6 improves healing in Wistar rats and rabbit ear models. No human wound-healing trial from this group has been published in indexed journals.
Verification
The COA standard, applied
Grade adversarially re-reviewed 2026-06-21 and downgraded to reflect the absence of formal human safety/efficacy data. Citations corrected 2026-06-22: (1) founding Bowers 1990 PMID fixed from 7883854 (wrong paper, Popovic 1995) to 2108187; (2) wound healing claim corrected from 'small Cuban human trial n=20' to animal-only (rats and rabbits); journal corrected from Int Wound J to Plastic Surgery International; claim grade adjusted to reflect animal-only evidence; (3) cardioprotection injury model corrected from ischemia-reperfusion to doxorubicin-induced cardiomyopathy; (4) synergy citation note added clarifying PMID 7617137 is a sleep-EEG study, not a dedicated synergy paper.
The full verification standard →Sources
Where this comes from
- PubMed: Bowers et al. 1990, founding human GHRP-6 study (PMID 2108187) ↗· 17 normal men; confirms dose-dependent GH pulse and GHRH synergy via IV administration. This is the correct PMID for the 1990 Bowers paper. The profile previously cited PMID 7883854, which is the Popovic 1995 hypothalamopituitary disconnection study.
- PubMed: GHRP-6 pharmacokinetics in healthy male volunteers (PMID 23099431) ↗· Nine male healthy volunteers. Establishes human PK profile: distribution half-life 7.6 min, elimination half-life 2.5 h after IV administration.
- PubMed: GHRP-6 stimulates sleep, GH, ACTH and cortisol in normal man (PMID 7617137) ↗· Sleep-EEG study confirming GH pulse and cortisol co-elevation in humans; primarily a nocturnal secretion and sleep study, not a dedicated GHRH-synergy comparison.
- PubMed: GHRP-6 wound healing, animal study only (PMID 27200188, Plastic Surgery International 2016) ↗· Animal model only (Wistar rats and rabbit ear wounds). No human subjects. Journal is Plastic Surgery International, not Int Wound J. No human wound-healing replication exists in the indexed literature.
- Frontiers in Pharmacology: Cardioprotection against doxorubicin-induced cardiomyopathy (2024) ↗· Rat model only. Shows PI3K/Akt, Bcl-2, and mitochondrial protection against doxorubicin cardiotoxicity. Injury model is chemotherapy-induced, not ischemia-reperfusion. No human cardiac data.
The four lenses reflect the evidence and the real-world record as of the last review and will change as data arrives. Real-world signal and reported feedback are anecdote, not proof. Nothing here is medical advice or a prescription.